Stoke Therapeutics

Stoke Therapeutics

Stoke Therapeutics

Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for the treatment of severe genetic diseases.
Type
B2b
Founded
2017
Raised
$130M
Follow us
Alexa global traffic share
Latest funding
$90,000,000
Venture capital (Series B) - 2018
RTW Investments
$40,000,000
Venture capital (Series A) - 2018
Apple Tree Partners
Team Size
10+
Employees
$90,000,000 Venture capital (Series B)
FinSMEs , PE HUB

Stoke Therapeutics Raises $90M in Series B Financing

Funding Health
FinSMEs

Stoke Therapeutics Raises $40M in Series A Financing

Science Health Funding